Ironwood Pharmaceuticals (IRWD) Expected to Announce Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:30 AM ET.

Ironwood Pharmaceuticals Stock Down 5.3%

Shares of Ironwood Pharmaceuticals stock opened at $3.75 on Tuesday. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.78. The firm has a market cap of $610.05 million, a P/E ratio of 23.44 and a beta of 0.17. The business has a 50-day moving average price of $4.26 and a 200 day moving average price of $2.77.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Wells Fargo & Company increased their target price on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the company an “equal weight” rating in a research report on Monday, January 5th. Citizens Jmp raised shares of Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price on the stock in a research note on Monday, January 5th. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Finally, Citigroup upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $3.68.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IRWD. Bank of America Corp DE raised its holdings in Ironwood Pharmaceuticals by 248.3% in the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock worth $15,321,000 after acquiring an additional 8,337,672 shares during the period. Millennium Management LLC grew its position in shares of Ironwood Pharmaceuticals by 186.6% in the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Ironwood Pharmaceuticals by 144.3% in the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after purchasing an additional 3,641,762 shares during the period. Marshall Wace LLP increased its stake in shares of Ironwood Pharmaceuticals by 616.3% in the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 3,436,036 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Ironwood Pharmaceuticals by 740.5% during the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after purchasing an additional 3,092,475 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.